The pandemic has shaken up investor priorities and changed the outlook for health care start-ups – or has it? Nooman Haque managing director, life sciences and healthcare at Silicon Valley Bank, gives his view of what has changed over the past year, and looks at future trends.

Gynesonics' Sonata System uses radiofrequency energy to ablate fibroids under real-time intrauterine sonography guidance.

Bristol makes its own deal with Celgene ally Dragonfly, while Gilead ends virology partnerships with Durect and Precision BioSciences.

The first of six new compounds are expected to begin Phase II testing soon as part of the UK’s ACCORD initiative, a randomized platform trial bringing together government, industry and research organisations to find potential treatments for COVID-19.